No increased survival from beta-blocker for moderate, advanced heart failure.A study sponsored by the National Heart, Lung, and Blood Institute National Heart, Lung, and Blood Institute, n.pr established in 1948, this division of the National Institutes of Health is responsible for research and education on cardiovascular, pulmonary, systemic diseases, and sleep disorders. (NHLBI NHLBI, n.pr See National Heart, Lung, and Blood Institute. ) and the Department of Veterans Affairs Veterans Affairs is a term of the business that deals with the relation between a government and its veteran communities, usually administered by the designated government agency. (VA) found that, overall, the betablocker bucindolol did not increase survival for moderate to severe heart failure. The results also showed racial differences in the drug's effects, although the reasons for these differences are not yet clear. Black heart failure patients received no benefit from bucindolol, while non-black patients treated with the drug lived longer. Non-black patients included whites, Hispanics, Asian/Pacific Islanders, and American Indian/Alaskan Natives. There were no differences by gender in the drug's effects. The findings of the Beta-Blocker Evaluation of Survival Trial (BEST), which contrast with those of other beta-blocker studies, appear in the May 31 issue of the New England Journal of Medicine The New England Journal of Medicine (New Engl J Med or NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It is one of the most popular and widely-read peer-reviewed general medical journals in the world. . |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion